Events Family Practice Hypertension IT 
Physician's Weekly
JUNE 11, 2025
Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults. The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure. . WEDNESDAY, June 11, 2025 (HealthDay News) — The U.S. All rights reserved.
Physician's Weekly
JUNE 18, 2025
WEDNESDAY, June 18, 2025 (HealthDay News) — The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in people with diabetes, according to a study published online June 9 in JAMA Internal Medicine. For each diet, adverse events were infrequent.
Expert insights. Personalized for you.
52 
Let's personalize your content